Clinical trial
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Opening soon · Phase 3 · 1 countries · Registry ID NCT07790861
Opening soonPhase 3Interventional
What this study is about
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Overweight
Full registry criteria
Inclusion Criteria: * Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and \<30 kg/m2 or ≥24.0 kg/m2 and \<28 kg/m2, and at least 1 of the following weight-related comorbidities at screening: * hypertension * dyslipidemia * obstructive sleep apnea * Fatty liver * cardiovascular disease * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma * Have a self-reported change in body weight \>5 kg within 90 days prior to screening * Had chronic or acute pancreatitis any time prior to screening * Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome
Treatments and study arms
Orforglipron
Drug
Administered orally.
Placebo
Drug
Administered orally.
Primary outcomes
Mean Percent Change From Baseline in Body WeightBaseline, Week 48
Study locations
13 locations were listed when this page was built. The first 40 are shown.
The first Affiliated Hospital, Zhejiang University School of Medicine🇨🇳 Hangzhou, China
Xiaomu LiPrincipal Investigator
The Fourth Affiliated Hospital of Harbin Medical University🇨🇳 Harbin, China
Study contactContact
ZhiFeng ChengPrincipal Investigator
The First Affiliated Hospital of Henan University of Science &Technology🇨🇳 Luoyang Shi, China
Study contactContact
Hongwei JiangPrincipal Investigator
Jiangxi Provincial People's Hospital🇨🇳 Nanchang, China
Study contactContact
Zongyou ChengPrincipal Investigator
Jiangsu Province Hospital🇨🇳 Nanjing, China
Study contactContact
Yun LiuPrincipal Investigator
The Second Affiliated Hospital of Nanjing Medical University🇨🇳 Nanjing, China
Study contactContact
Yibing LuPrincipal Investigator